IGI Logo

Below are Views On Jubilant Pharmova up by 7% on success in Remdesivir oral formulation By Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

 

Jubilant Pharma Limited, a subsidiary of Jubilant Pharmova Limited, announces successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of remdesivir against the commercially available injectable formulation of remdesivir. Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI). Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients. The proposed oral treatment is expected to be for 5 days, a duration similar to the injectable dosage form. Remdesivir is the first and the only antiviral drug fully approved by the US FDA for the treatment of patients with COVID-19 requiring hospitalization.

We expect this to be a very short-term benefit for the company, as we expect more players to develop this medicine for covid 19 and once cases in India come down the use of remdesivir will also come down.

 

Above views are of the author and not of the website kindly read disclaimer